Standout Papers

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): l... 2022 2026 2023 2024169
  1. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (2022)
    Robert J. Motzer, Thomas Powles et al. The Lancet Oncology

Immediate Impact

13 by Nobel laureates 5 from Science/Nature 64 standout
Sub-graph 1 of 21

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
1 intermediate paper

Works of Burçin Şimşek being referenced

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
2020

Author Peers

Author Last Decade Papers Cites
Burçin Şimşek 570 492 36 252 39 1.0k
Jing Zhao 362 685 4 199 62 1.1k
Ian Rabinowitz 380 344 2 226 48 1.3k
Jean-Michel Vannetzel 379 701 11 158 27 1.3k
Leonard R. Henry 277 488 13 206 41 1.3k
Stefania Scarpino 267 347 4 364 50 1.3k
Roberta D’Alessandro 147 394 11 288 57 1.2k
Djelila Allouache 753 774 8 362 36 1.4k
Hong Jian 347 373 48 288 48 940
Tatjana Kolevska 185 456 72 255 47 1.2k
Einat Shacham‐Shmueli 316 980 21 215 69 1.3k

All Works

Loading papers...

Rankless by CCL
2026